
IGF-1 LR3
Long-acting version of insulin-like growth factor 1, studied for muscle cell growth and repair.
For Research Use Only
Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.
Pricing coming soon
Contact us for a quote on this batch.
Bacteriostatic water included
About this peptide
IGF-1 LR3 is a modified form of IGF-1 — the hormone the liver releases in response to growth hormone, and the one that actually tells muscle and other tissues to grow. Two changes (an extra 13-amino-acid tail and one swapped amino acid) stop it from being locked up by binding proteins in the blood, so it stays active far longer than natural IGF-1. Researchers use it widely in cell culture and muscle-growth studies.
Why researchers reach for IGF-1 LR3
Muscle-growth research
Studied for driving muscle-cell growth and the formation of new muscle fibres in laboratory models.
Extended activity
Resists binding proteins, giving a much longer active window than natural IGF-1 — useful for consistent experimental exposure.
Cell proliferation standard
A widely used growth supplement in cell-culture and bioprocessing research.
Key features
- 98%+ purity verified by HPLC
- 83-amino-acid IGF-1 analogue
- Lyophilised powder for stability
- 1 mg research vial
- Bacteriostatic water included
- For laboratory research use only
How it works
IGF-1 receptor activation
Binds the IGF-1 receptor and switches on the PI3K/Akt and MAPK pathways that drive cell growth and survival.
Reduced binding-protein capture
The Arg3 substitution and N-terminal extension cut binding to IGFBPs, leaving more free, active peptide.
Satellite-cell signalling
Studied for activating muscle stem (satellite) cells involved in repair and hypertrophy.
Research dosage guidelines
Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.
| Range | Reported dose | Note |
|---|---|---|
| Reported research range | 20–100 mcg | Per administration in research protocols; no human clinical dosing has been published for the LR3 analogue. |
| Frequency | 1× daily | Protocols describe short cycles of around 4 weeks. |
| Typical reconstitution | 2 mL bacteriostatic water | Yields 0.5 mg/mL (500 mcg/mL). |
Tracking this compound? Registered researchers can log active IGF-1 LR3 protocols in their private Research Log.
Timing in research protocols
No human timing data — evidence is cell-culture and animal only.
- The LR3 analogue has not been through human clinical trials, so no clock time, meal relationship or cycle length is established.
Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.
Technical specifications
- Scientific name
- Long Arg3 insulin-like growth factor-1 (LR3-IGF-1)
- Sequence
- MFPAMPLSSLFVN + [Arg3]IGF-1 (83 amino acids)
- CAS number
- 946870-92-4
- Molecular weight
- ~9111 Da
- Purity
- 98%+ (HPLC)
- Form
- Lyophilised white powder
- Vial size
- 1 mg
- Reconstitution
- 2 ml bacteriostatic water
- Storage (unopened)
- -20 degrees C, protected from light
- Storage (reconstituted)
- 2-8 degrees C, use within 30 days
Published research
Peer-reviewed literature on IGF-1 LR3. Links open in a new tab.
Research use notice
IGF-1 LR3 is supplied strictly for laboratory research. No human clinical dosing protocols exist for this analogue. Not for human or veterinary use, ingestion, or clinical application.
